WeightWatchers Launches Compounded Novo Nordisk Drug Amid Health Innovations

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA approval for miscarriage use of Mifeprex, Pfizer and BioNTech invalidating CureVac's patents, declining RSV vaccine sales, Siga Technologies supplying mpox therapy in Morocco, and Maven Clinic's $1.7 billion valuation.

WeightWatchers is expanding its weight-management programs by offering a compounded version of Novo Nordisk's Wegovy drug, elevating its shares by 47%. The demand for weight-loss medications like Wegovy and Zepbound, which can help patients lose up to 20% of their body weight, has resulted in shortages.

Danco Laboratories is preparing to request the FDA's approval to use its abortion pill regimen, Mifeprex, for managing miscarriages. Meanwhile, Pfizer and BioNTech succeeded in invalidating two of CureVac's patents related to mRNA technology essential for their COVID-19 vaccine development.

The sale of RSV vaccines from GSK and Pfizer in the U.S. has decreased significantly, as fewer people line up due to regulator constraints. Additionally, the Biden administration mandates replacing all lead pipes nationwide within a decade to address environmental and racial disparity concerns.

(With inputs from agencies.)